The efficacy of dapagliflozin in preventing contrast-associated acute kidney injury

Evaluating the Effects of Dapagliflozin on Preventing Contrast Associated Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention, a Feasibility Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181026041471N2

Enrollment

150

Registered

2025-08-11

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive 20 mg of dapagliflozin immediately after randomization and before entering the cath lab, followed by 10 mg daily for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years old hospitalized with acute coronary syndrome (i.e. ST elevation or NST elevation myocardial infarction or unstable angina) diagnosis and candidates for coronary angiography or angioplasty Signed informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients previously treated with SGLT2 inhibitor drugs Creatinine clearance less than 25 ml/min Chronic liver disease and cirrhosis (Child-Pugh C) Drug allergy or history of severe hypersensitivity to dapagliflozin or its components Non-consent to participate in the study History of recurrent urinary tract infections History of ketoacidosis Pregnancy or breastfeeding Type 1 diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Feasibility of conducting the randomized controlled trial. Timepoint: 7 days after intervention. Method of measurement: Investigators' opinion.	—

Secondary

Measure	Time frame
?The incidence of contrast- associated acute kidney injury defined by KDIGO criteria. Timepoint: 7 days after intervention. Method of measurement: Lab findings (serum creatinine) and urine output.;Incidence of adverse drug reactions. Timepoint: 7 days after randomization. Method of measurement: Clinical Records.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHessam Kakavand

Iran University of Medical Sciences

hessamkakavand@yahoo.com+98 21 86701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026